Modulation of butyrate anticancer activity by solid lipid nanoparticle delivery: An in vitro investigation on human breast cancer and leukemia cell lines

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 17, Issue 2, 2014, Pages 231-247

  Foglietta, Federica ^a   Serpe, Loredana ^a   Canaparo, Roberto ^a   Vivenza, Nicoletta ^b   Riccio, Giovanna ^b   Imbalzano, Erica ^a   Gasco, Paolo ^b   Zara, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NANOVECTOR S R L   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYCLIN DEPENDENT KINASE; HISTONE DEACETYLASE; MESSENGER RNA; PROTEIN P21; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; LIPID; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE GENE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE TARGETING; HISTONE DEACETYLASE GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; NANOPHARMACEUTICS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BREAST TUMOR; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HL 60 CELL LINE; LEUKEMIA; MCF 7 CELL LINE; PARTICLE SIZE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BUTYRATES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA; LIPIDS; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; TUMOR CELLS, CULTURED;

EID: 84901794837     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3xp4r     Document Type: Article

References (56)

1. Pajak B, Orzechowski A, Gajkowska B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv Med Sci. 2007;52:83-8.
2. Goncalves P, Araujo JR, Martel F. Characterization of butyrate uptake by nontransformed intestinal epithelial cell lines. J Membr Biol. 2011;240:35-46.
3. Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res. 2002;277:31-47.
4. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res. 2004;298:560-73.
5. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 1977;268:462-4.
6. Sealy L, Chalkley R. The effect of sodium butyrate on histone modification. Cell. 1978;14:115-21.
7. Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer. 2006;5:71.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-28.
9. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23:3971-93.
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
11. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275-83.
12. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862-73.
13. Lavelle D, Chen YH, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol. 2001;68:170-8.
14. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002;1:937-41.
15. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004;23:21-9.
16. Tonelli R, Sartini R, Fronza R, Freccero F, Franzoni M, Dongiovanni D, et al. G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLLAF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia. 2006;20:1307-10.
17. Lindemann RK, Gabrielli B, Johnstone RW. Histonedeacetylase inhibitors for the treatment of cancer. Cell Cycle. 2004;3:779-88.
18. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factorrelated apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004;64:2580-9.
19. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, et al. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer. 2010;9:275.
20. Kobayashi N, Kunieda T, Sakaguchi M, Okitsu T, Totsugawa T, Maruyama M, et al. Active expression of p21 facilitates differentiation of immortalized human hepatocytes. Transplant Proc. 2003;35:433-4.
21. Merchant JL, Bai L, Okada M. ZBP-89 mediates butyrate regulation of gene expression. J Nutr. 2003;133(7 Suppl):2456S-60S.
22. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem. 2005;40:1-13.
23. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15:3958-69.
24. Cuff MA, Shirazi-Beechey SP. The importance of butyrate transport to the regulation of gene expression in the colonic epithelium. Biochem Soc Trans. 2004;32:1100-2.
25. Astbury SM, Corfe BM. Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature. Curr Drug Metab. 2012;13:815-21.
26. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003;100:8412-7.
27. Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S, Jr., Mariadason JM, et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A. 2006;103:7270-5.
28. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006;66:11560-4.
29. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med. 2008;59:251-65.
30. Pellizzaro C, Coradini D, Morel S, Ugazio E, Gasco MR, Daidone MG. Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res. 1999;19:3921-5.
31. Gasco M.R. Solid lipidic nanospheres suitable to a fast internalization into cells. Patent WO 2000030620 A1. 2000
32. Ugazio E, Marengo E, Pellizzaro C, Coradini D, Peira E, Daidone MG, et al. The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation. Eur J Pharm Biopharm. 2001;52:197-202.
33. Brioschi A, Zenga F, Zara GP, Gasco MR, Ducati A, Mauro A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res. 2007;29:324-30.
34. Salomone B, Ponti R, Gasco MR, Ugazio E, Quaglino P, Osella-Abate S, et al. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid prodrug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis. 2000;18:663-73.
35. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58:673-80.
36. Serpe L, Laurora S, Pizzimenti S, Ugazio E, Ponti R, Canaparo R, et al. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs. 2004;15:525-36.
37. Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules. 2008;13:230-54.
38. Minelli R, Serpe L, Pettazzoni P, Minero V, Barrera G, Gigliotti C, et al. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br J Pharmacol. 2012;166:587-601.
39. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161-72.
40. Souto EB, Muller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol. 2010;197:115-41.
41. Bruns T, Peter J, Hagel S, Herrmann A, Stallmach A. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol. 2011;164:346-56.
42. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-22.
43. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-96.
44. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 2008;348:137-45.
45. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da- Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430:216-27.
46. Chopin V, Toillon RA, Jouy N, Le Bourhis X. Sodium butyrate induces P53-independent, Fasmediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol. 2002;135:79-86.
47. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene. 2004;23:6304-15.
48. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2- related protein Bad. Brain Tumor Pathol. 2001;18:109-14.
49. Chirakkal H, Leech SH, Brookes KE, Prais AL, Waby JS, Corfe BM. Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. Oncogene. 2006;25:7192-200.
50. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 2008;112:2896-905.
51. Siavoshian S, Blottiere HM, Cherbut C, Galmiche JP. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells. Biochem Biophys Res Commun. 1997;232:169-72.
52. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 2004;64:7706-10.
53. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007;67:3145-52.
54. Palani CD, Beck JF, Sonnemann J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs. 2012;30:25-36.
55. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol. 2008;153:657-68.
56. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95:6791-6.